MariMed Inc (TSE:MRMD)
:MRMD
Want to see TSE:MRMD full AI Analyst Report?
MRMD Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.48
Previous CloseN/A
Volume0.00
Average Volume (3M)46.35K
Market Cap
C$46.30M
Enterprise ValueC$125.02M
Total Cash (Recent Filing)C$8.88M
Total Debt (Recent Filing)C$100.09M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
May 13, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding397,882,750
10 Day Avg. Volume89,801
30 Day Avg. Volume46,354
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.66
Price to Sales (P/S)0.21
P/FCF Ratio5.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.34Price Target Upside239.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)C$227.13M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & Channel DiversificationMulti-year revenue growth and a balanced wholesale/retail mix create a durable sales base. Broadening wholesale penetration cushions against single-channel shocks, enables scale economics in production and distribution, and supports repeatable top-line expansion over the next 2–6 months.
Positive Cash Generation And Adjusted EBITDA StreakConsistent positive adjusted EBITDA and a return to positive free cash flow signal improving cash conversion. This operational cash buffer reduces reliance on external financing, supports reinvestment in brands and operations, and bolsters near-term resilience despite legacy losses.
Strong Brands And High Market PenetrationCategory-leading brands and high dispensary penetration drive shelf placement and recurring demand. Brand equity plus a growing Thrive loyalty program improve customer retention and distribution leverage, supporting sustainable volume and margin improvement as the company internalizes more branded SKUs.
Bears Say
Material Margin CompressionSteady gross margin erosion reflects structural pricing pressure in mature markets that undermines unit economics. Lower margins constrain ability to absorb SG&A and interest costs, impede return-to-profitability efforts, and make sustained bottom-line recovery more difficult without durable pricing or cost shifts.
Strained Capital Structure And Rising LeverageSharp leverage increase limits financial flexibility and raises default and refinancing risk. Higher interest expense and concentrated equity erosion reduce capacity for strategic investment; recent restructuring removed near-term obligation but added notes and senior preferred, increasing long-term servicing and dilution risks.
Retail Weakness & Timing Risk For New MarketsSignificant retail declines in key states and reliance on uncertain Pennsylvania and New York contributions create execution and timing risk. If new-market ramps miss expectations, wholesale and brand gains may not offset retail softness, prolonging margin pressure and cash stress over the medium term.
MariMed News
MRMD FAQ
What was MariMed Inc’s price range in the past 12 months?
MariMed Inc lowest stock price was C$0.06 and its highest was C$0.48 in the past 12 months.
What is MariMed Inc’s market cap?
MariMed Inc’s market cap is C$46.30M.
When is MariMed Inc’s upcoming earnings report date?
MariMed Inc’s upcoming earnings report date is May 13, 2026 which is tomorrow.
How were MariMed Inc’s earnings last quarter?
MariMed Inc released its earnings results on Mar 11, 2026. The company reported C$0.008 earnings per share for the quarter, beating the consensus estimate of -C$0.014 by C$0.022.
Is MariMed Inc overvalued?
According to Wall Street analysts MariMed Inc’s price is currently Undervalued.
Does MariMed Inc pay dividends?
MariMed Inc does not currently pay dividends.
What is MariMed Inc’s EPS estimate?
MariMed Inc’s EPS estimate is -0.01.
How many shares outstanding does MariMed Inc have?
MariMed Inc has 397,882,750 shares outstanding.
What happened to MariMed Inc’s price movement after its last earnings report?
MariMed Inc reported an EPS of C$0.008 in its last earnings report, beating expectations of -C$0.014. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MariMed Inc?
Currently, no hedge funds are holding shares in TSE:MRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MariMed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.40%
12-Months-Change
Fundamentals
Return on Equity
-24.95%
Trailing 12-Months
Asset Growth
-2.14%
Trailing 12-Months
Company Description
MariMed Inc
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
MRMD Company Deck
MRMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic tone: MariMed reported continued brand and wholesale momentum (category leadership, expanded penetration, wholesale growth, Delaware AU traction), maintained positive adjusted EBITDA streak, and executed balance sheet actions to improve flexibility. However, the company is facing notable margin and retail headwinds in mature markets (notably Illinois and Massachusetts), experienced declines in EBITDA and operating income YoY, and has limited near‑term cash reserves. Management emphasized disciplined cost control, asset‑light licensing expansion, and selective M&A, while acknowledging timing risk for new market contributions.View all TSE:MRMD earnings summariesMRMD Stock 12 Month Forecast
Average Price Target
C$0.34
▲(239.93% Upside)
Technical Analysis
Options Prices
Currently, No data available
---